MINT-ATENOL TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

ATENOLOL

Prieinama:

MINT PHARMACEUTICALS INC

ATC kodas:

C07AB03

INN (Tarptautinis Pavadinimas):

ATENOLOL

Dozė:

25MG

Vaisto forma:

TABLET

Sudėtis:

ATENOLOL 25MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

30/100/500

Recepto tipas:

Prescription

Gydymo sritis:

BETA-ADRENERGIC BLOCKING AGENTS

Produkto santrauka:

Active ingredient group (AIG) number: 0113847004; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2011-05-31

Prekės savybės

_______________________________________________________________________________________
_MINT-ATENOL Product Monograph _
Page 1 of 28
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MINT-ATENOL
Atenolol Tablets, BP
Tablets, 25 mg, oral
Beta-adrenergic receptor blocking agent
ATC Code: C07AB
Mint Pharmaceuticals Inc.
Date of Initial Authorization:
6575 Davand Drive
May 6, 2011
Mississauga, Ontario
Canada L5T 2M3
Date of Revision:
May 20, 2022
Control #: 259456
_______________________________________________________________________________________
_MINT-ATENOL Product Monograph _
Page 2 of 28
RECENT MAJOR LABEL CHANGES
7 Warnings and Precautions, 7.1.1 Pregnant Women
05/2022
Table of Contents
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
1.
INDICATIONS..........................................................................................................
3
1.1
Pediatrics...........................................................................................................
3
1.2 Geriatrics
...........................................................................................................
3
2.
CONTRAINDICATIONS..........................................................................................
3
3. SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................. 4
4. DOSAGE AND
ADMINISTRATION........................................................................
4
4.2 Recommended Dose and Dosage
Adjustment.................................................... 4
4.5 Missed Dose
......................................................................................................
5
5. OVERDOSAGE
.......................................................................................................
5
6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ............. 6
7. WARNINGS AND PRECAUTIONS
........................................................................
6
7.1 Special Populations
.......................